Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG035
MIFTS: 53

Lung Large Cell Carcinoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Large Cell Carcinoma

About this section

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 15
Large Cell Carcinoma of Lung 12 70
Large Cell Lung Carcinoma 12 17
Large Cell Lung Cancer 54

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Respiratory diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4556
NCIt 50 C4450
SNOMED-CT 67 254629004
UMLS 70 C0345958
Sources

Summaries for Lung Large Cell Carcinoma

About this section
MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to pulmonary large cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and thymus, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Large-cell carcinoma (LCC, LCLC) is a heterogeneous group of undifferentiated malignant neoplasms that... more...

Sources

Related Diseases for Lung Large Cell Carcinoma

About this section

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 186)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 31.7 SYP NCAM1 CHGA
2 large cell neuroendocrine carcinoma 31.1 SYP NTRK3 NKX2-1 NCAM1 CHGA
3 lung squamous cell carcinoma 30.2 TTN ROS1 FGFR1 DDR2
4 adenocarcinoma 29.7 ROS1 NTRK3 NKX2-1 FGFR1 EPHA5 EPHA3
5 neuroendocrine carcinoma 29.5 SYP NKX2-1 NCAM1 CHGA
6 small cell carcinoma 29.4 SYP NKX2-1 NCAM1 CHGA
7 lung cancer 29.0 SYP ROS1 NME1 NKX2-1 NCAM1 MYO18B
8 large cell carcinoma 28.9 SYP STK33 ROS1 NTRK3 NKX2-1 NCAM1
9 lung mixed small cell and squamous cell carcinoma 11.3
10 malignant giant cell tumor of the tendon sheath 10.4 ROS1 NTRK3
11 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.4 FGFR1 ABL1
12 perinephritis 10.3 TTN ROS1
13 rosette-forming glioneuronal tumor 10.3 SYP FGFR1
14 spinal cord oligodendroglioma 10.3 SYP FGFR1
15 mucinous lung adenocarcinoma 10.2 ROS1 NKX2-1
16 primary hepatic neuroendocrine carcinoma 10.2 SYP CHGA
17 auditory system benign neoplasm 10.2 SYP CHGA
18 auditory system cancer 10.2 SYP CHGA
19 acinar cell cystadenocarcinoma 10.2 SYP CHGA
20 vulvar eccrine porocarcinoma 10.2 SYP CHGA
21 cauda equina neoplasm 10.2 SYP CHGA
22 gastrointestinal neuroendocrine benign tumor 10.2 SYP CHGA
23 ampulla of vater benign neoplasm 10.2 SYP CHGA
24 appendix carcinoid tumor 10.2 SYP CHGA
25 vaginal tubulovillous adenoma 10.2 SYP CHGA
26 mixed ductal-endocrine carcinoma 10.2 SYP CHGA
27 middle ear adenoma 10.2 SYP CHGA
28 duodenal benign neoplasm 10.2 SYP CHGA
29 breast papillary carcinoma 10.2 SYP CHGA
30 thrombocytosis 10.2
31 gastric neuroendocrine neoplasm 10.2 SYP CHGA
32 giant cell glioblastoma 10.2 SYP MTOR FGFR1
33 appendix adenocarcinoma 10.2 SYP CHGA
34 gastric hemangioma 10.2 SYP CHGA
35 pineocytoma 10.2 SYP CHGA
36 pancreatic gastrinoma 10.1 SYP CHGA
37 anal neuroendocrine tumor 10.1 SYP NCAM1
38 cervix small cell carcinoma 10.1 SYP CHGA
39 adrenal neuroblastoma 10.1 SYP CHGA
40 thymus clear cell carcinoma 10.1 TTN NKX2-1
41 thymus basaloid carcinoma 10.1 SYP NKX2-1
42 lung meningioma 10.1 SYP NKX2-1
43 lung combined type small cell carcinoma 10.1 SYP NCAM1
44 gastrointestinal neuroendocrine tumor 10.1 SYP MTOR CHGA
45 hypoganglionosis 10.1 SYP NCAM1
46 vaginal adenoma 10.1 SYP CHGA
47 ureter transitional cell carcinoma 10.1 NCAM1 CHGA
48 glomangiosarcoma 10.1 SYP NCAM1
49 cerebellopontine angle primitive neuroectodermal tumor 10.1 SYP NCAM1
50 vaginal benign neoplasm 10.1 SYP CHGA

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma
Sources

Symptoms & Phenotypes for Lung Large Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.82 MTOR EPHA3
2 Decreased viability GR00055-A-2 10.82 MTOR EPHA3
3 Decreased viability GR00055-A-3 10.82 EPHA3
4 Decreased viability GR00221-A-1 10.82 ABL1 DDR2 FGFR1 MTOR NME1 ROS1
5 Decreased viability GR00221-A-2 10.82 ABL1 DDR2 FGFR1 NME1 ROS1 STK33
6 Decreased viability GR00221-A-3 10.82 ABL1 EPHA5
7 Decreased viability GR00221-A-4 10.82 DDR2 MTOR STK33 EPHA3 EPHA5 NTRK3
8 Decreased viability GR00249-S 10.82 NME1 ROS1 EPHA3
9 Decreased viability GR00301-A 10.82 EPHA3
10 Decreased viability GR00342-S-1 10.82 ABL1 MTOR ROS1 EPHA3 TTN
11 Decreased viability GR00342-S-2 10.82 ABL1 MTOR
12 Decreased viability GR00342-S-3 10.82 ABL1 TTN
13 Decreased viability GR00386-A-1 10.82 FGFR1
14 Decreased viability GR00402-S-2 10.82 DDR2 NME1
15 Decreased cell migration GR00055-A-1 10.01 ABL1 ALPK3
16 Decreased cell migration GR00055-A-2 10.01 NCAM1
17 Decreased cell migration GR00055-A-3 10.01 MTOR NCAM1
18 Decreased substrate adherent cell growth GR00193-A-1 9.8 ROS1
19 Decreased substrate adherent cell growth GR00193-A-2 9.8 ABL1 ALPK3 EPHA3 MTOR ROS1
20 Decreased substrate adherent cell growth GR00193-A-4 9.8 ABL1
21 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.62 EPHA3 FGFR1 MTOR TTN
22 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.54 DDR2 EPHA3 STK33
23 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.13 FGFR1 MTOR ROS1
24 Increased viability GR00386-A-1 8.32 ABL1

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.07 ABL1 ALPK3 CHGA DDR2 EPHA3 FGFR1
2 cardiovascular system MP:0005385 10.06 ABL1 ALPK3 CHGA DDR2 EPHA3 FGFR1
3 muscle MP:0005369 9.76 ABL1 ALPK3 CHGA DDR2 FGFR1 MTOR
4 nervous system MP:0003631 9.73 ABL1 ALPK3 CHGA DDR2 EPHA5 FGFR1
5 no phenotypic analysis MP:0003012 9.17 CHGA DDR2 FGFR1 MTOR NKX2-1 NTRK3
Sources

Drugs & Therapeutics for Lung Large Cell Carcinoma

About this section

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
2
Carboplatin Approved Phase 4 41575-94-4 10339178 498142 38904
3
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
4 Tubulin Modulators Phase 4
5 Antimitotic Agents Phase 4
6 Albumin-Bound Paclitaxel Phase 4
7 Immunosuppressive Agents Phase 4
8 Immunologic Factors Phase 4
9
Etoposide Approved Phase 3 33419-42-0 36462
10
Vinblastine Approved Phase 3 865-21-4 13342 241903
11
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
12
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
13
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
15
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
16
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
17
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
18
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
19
Lenograstim Approved, Investigational Phase 3 135968-09-1
20
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
22
Tirapazamine Investigational Phase 3 27314-97-2
23 Hematinics Phase 3
24 Etoposide phosphate Phase 3
25 Epoetin alfa Phase 3 113427-24-0
26 Immunoglobulins Phase 3
27 Antibodies Phase 3
28 Mitogens Phase 3
29 Immunoglobulins, Intravenous Phase 3
30 Antibodies, Monoclonal Phase 3
31 Immunoglobulin G Phase 3
32 Endothelial Growth Factors Phase 3
33 Angiogenesis Inhibitors Phase 3
34 Vitamin B9 Phase 3
35 Folic Acid Antagonists Phase 3
36 Vitamin B Complex Phase 3
37 Folate Phase 3
38 Anti-Bacterial Agents Phase 3
39 Antirheumatic Agents Phase 3
40 Anti-Inflammatory Agents Phase 3
41 Cyclooxygenase Inhibitors Phase 3
42 Cyclooxygenase 2 Inhibitors Phase 3
43 Analgesics Phase 3
44 Anti-Inflammatory Agents, Non-Steroidal Phase 3
45 Analgesics, Non-Narcotic Phase 3
46
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
47
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
48
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
49
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
50
Cobalt Approved, Experimental Phase 2 7440-48-4 104729

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
3 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
4 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
5 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
6 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
7 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
8 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
9 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
10 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
11 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
12 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
13 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
14 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
15 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 Paclitaxel;Carboplatin;Pemetrexed Disodium Heptahydrate
16 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
17 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
18 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
19 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
20 Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study. Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
21 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
22 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
23 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
24 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
25 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
26 A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
27 Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase â…¡a Trial Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
28 Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer Unknown status NCT00979212 Phase 2 panitumumab;carboplatin;paclitaxel
29 A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
30 A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
31 A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
32 First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
33 Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
34 A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2) Completed NCT00661193 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel
35 A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer Completed NCT00960999 Phase 2
36 A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
37 A Feasibility Study Investigating Translational Science in Chemotherapy-Naive Patients With Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Treated With the EGFR-TKI, Erlotinib Completed NCT00550537 Phase 2 bevacizumab;carboplatin;erlotinib hydrochloride;paclitaxel
38 A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
39 Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
40 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Operable Stage I/II Non-Small Cell Lung Cancer Completed NCT00551369 Phase 2
41 A Phase II Study of Bevacizumab Plus Docetaxel and Gemcitabine in Subjects With Advanced, Previously Untreated, Non-Squamous Non-Small Cell Lung Cancer Completed NCT00970684 Phase 2 docetaxel;gemcitabine hydrochloride
42 A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
43 Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed NCT00234052 Phase 2 carboplatin;pemetrexed
44 Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70 Completed NCT00227708 Phase 2 docetaxel
45 A Phase II Study of Temozolomide and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC) Completed NCT00080938 Phase 2 Temozolomide
46 A Randomized Phase II Study Of Triapine® Alone Versus Triapine and Gemcitabine As Second-Line Treatment Of Advanced Non-Small-Cell-Lung Cancer In Patients Who Had Prior Gemcitabine With Evaluation Of The Effect Of Triapine® On Gemcitabine Pharmacokinetics and Cellular Uptake In Peripheral Mononuclear Cells Completed NCT00077415 Phase 2 gemcitabine hydrochloride;triapine
47 Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
48 Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or With Performance Status 2 Completed NCT00026156 Phase 2 docetaxel;vinorelbine tartrate
49 Phase II Study of Carboplatin, Irinotecan, and Thalidomide in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00025285 Phase 2 carboplatin;irinotecan hydrochloride;thalidomide
50 Phase II Randomized Trial of Gemcitabine/Docetaxel and Gemcitabine/Irinotecan in Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00004139 Phase 2 docetaxel;gemcitabine hydrochloride;irinotecan hydrochloride

Search NIH Clinical Center for Lung Large Cell Carcinoma

Sources

Genetic Tests for Lung Large Cell Carcinoma

About this section
Sources

Anatomical Context for Lung Large Cell Carcinoma

About this section

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

40
Lung, Lymph Node, Thymus, Thyroid, Spinal Cord, Breast, Skin
Sources

Publications for Lung Large Cell Carcinoma

About this section

Articles related to Lung Large Cell Carcinoma:

(show top 50) (show all 226)
# Title Authors PMID Year
1
Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. 61
33568870 2021
2
Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer. 61
33628824 2021
3
Anticancer Activity of Novel Plant Extracts and Compounds from Adenosma bracteosum (Bonati) in Human Lung and Liver Cancer Cells. 61
32599892 2020
4
Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A. 61
32194720 2020
5
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. 61
33584678 2020
6
A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. 61
32944497 2020
7
Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. 61
31531741 2019
8
Cancer-associated Retinopathy with Neuroendocrine Combined Large-cell Lung Carcinoma and Adenocarcinoma. 61
31327819 2019
9
Unraveling the large cell lung carcinoma-specific miRNA profile and the downstream regulation network. 61
31555828 2019
10
Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. 61
31360195 2019
11
Doxycycline inhibits electric field-induced migration of non-small cell lung cancer (NSCLC) cells. 61
31147570 2019
12
Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. 61
31179087 2019
13
Connexin43 Suppresses Lung Cancer Stem Cells. 61
30717421 2019
14
Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT. 61
31496800 2019
15
Clinical characteristics and prognosis of basaloid squamous cell carcinoma of the lung: a population-based analysis. 61
31106047 2019
16
Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma. 61
30166013 2018
17
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 61
29988660 2018
18
Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. 61
29570944 2018
19
Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria. 61
29525405 2018
20
Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin. 61
29541373 2018
21
The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro. 61
29230631 2018
22
Unravelling the Long Non-Coding RNA Profile of Undifferentiated Large Cell Lung Carcinoma. 61
29657301 2018
23
Laparoscopic Splenectomy for Splenic Metastasis from Primary Lung Carcinoma. 61
29732229 2018
24
Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer. 61
28176646 2018
25
Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer. 61
28993508 2018
26
Correlation between STK33 and the pathology and prognosis of lung cancer. 61
29085482 2017
27
TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. 61
28789440 2017
28
[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. 61
28468033 2017
29
Comparison of human lung cancer cell radiosensitivity after irradiations with therapeutic protons and carbon ions. 61
27633574 2017
30
[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation]. 61
28219201 2017
31
A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity. 61
27894849 2017
32
Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. 61
28790845 2017
33
Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach. 61
28105238 2016
34
Differentiating brain metastases from different pathological types of lung cancers using texture analysis of T1 postcontrast MR. 61
26621795 2016
35
[Two Cases of Small Intestinal Metastasis of Lung Cancer]. 61
28133150 2016
36
Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. 61
27301951 2016
37
Discovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs. 61
27679544 2016
38
Blood-borne miRNA profile-based diagnostic classifier for lung adenocarcinoma. 61
27507195 2016
39
Treatment of lung large cell neuroendocrine carcinoma. 61
26943800 2016
40
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. 61
26942444 2016
41
Four Cu(ii) complexes based on antitumor chelators: synthesis, structure, DNA binding/damage, HSA interaction and enhanced cytotoxicity. 61
27071545 2016
42
[Large-cell lung carcinoma by the 2015 WHO classification: a clinicopathologic analysis of 93 cases]. 61
27033385 2016
43
Brachial metastatic plexopathy as the inaugural manifestation of lung cancer: multimodality imaging. 61
30460024 2016
44
[A clinical review of 3 cases of children with bronchial tumor]. 61
26696483 2015
45
Digging Deep for New Compounds from the Compass Plant, Silphium laciniatum. 61
26287548 2015
46
Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology. 61
25793929 2015
47
Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. 61
26170921 2015
48
Lung transthoracic ultrasound elastography imaging and guided biopsies of subpleural cancer: a preliminary report. 61
24951615 2015
49
Large cell lung carcinoma with rhabdoid phenotype: Report of a rare entity presenting with chest wall involvement. 61
26458655 2015
50
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. 61
25937073 2015
Sources

Variations for Lung Large Cell Carcinoma

About this section

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 2927)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 15
2 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 15
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 15
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 15
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 15
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 15
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 15
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 15
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 15
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 15
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 15
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 15
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 15
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 15
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 15
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 15
17 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 15
18 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 15
19 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 15
20 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 15
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 15
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 15
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 15
24 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 15
25 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
26 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 15
27 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
28 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
29 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
30 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
31 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
32 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
33 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
34 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 15
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 15
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 15
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 15
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 15
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 15
42 COSM98261314 WNK3 lung,NS,carcinoma,large cell carcinoma c.4458G>T p.L1486F 23:54236967-54236967 15
43 COSM144807452 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 15
44 COSM98245214 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 15
45 COSM89575026 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 15
46 COSM99767946 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 15
47 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 15
48 COSM121848752 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 15
49 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 15
50 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 15
Sources

Expression for Lung Large Cell Carcinoma

About this section
Search GEO for disease gene expression data for Lung Large Cell Carcinoma.
Sources

Pathways for Lung Large Cell Carcinoma

About this section

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.56 ROS1 NTRK3 MYO18B MTOR FGFR1 EPHA5
2
Akt Signaling 63
Show member pathways
 13.17 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
3
p70S6K Signaling 63
Show member pathways
 12.73 NTRK3 MTOR FGFR1 EPHA5 EPHA3 DDR2
4
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 12.53 ROS1 NTRK3 MYO18B FGFR1 EPHA5 EPHA3
5
G-protein signaling RAC1 in cellular process 23
Show member pathways
 11.8 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
6
Guidance Cues and Growth Cone Motility 63
11.63 NTRK3 EPHA5 EPHA3 ABL1
7
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.53 SYP NCAM1 FGFR1
8
Central carbon metabolism in cancer 36
11.43 NTRK3 MTOR FGFR1
9
Tyrosine Kinases / Adaptors 4
11.27 ROS1 FGFR1 EPHA5 EPHA3 DDR2 ABL1
10
G-protein signaling_Rap2B regulation pathway 23
10.7 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
Sources

GO Terms for Lung Large Cell Carcinoma

About this section

Cellular components related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.5 SYP STK33 ROS1 NME1 EPHA5 CHGA
2 receptor complex GO:0043235 9.1 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
2 protein phosphorylation GO:0006468 9.9 TTN STK33 ROS1 NTRK3 MTOR FGFR1
3 axon guidance GO:0007411 9.81 NKX2-1 NCAM1 EPHA5 EPHA3
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
5 protein autophosphorylation GO:0046777 9.77 STK33 MTOR FGFR1 DDR2 ABL1
6 neuron migration GO:0001764 9.75 NTRK3 NKX2-1 FGFR1
7 regulation of GTPase activity GO:0043087 9.73 MTOR EPHA5 EPHA3
8 positive regulation of neuron projection development GO:0010976 9.73 NTRK3 NME1 MTOR EPHA3
9 positive regulation of kinase activity GO:0033674 9.73 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
10 ephrin receptor signaling pathway GO:0048013 9.72 NTRK3 EPHA5 EPHA3
11 regulation of actin cytoskeleton organization GO:0032956 9.71 MTOR EPHA5 EPHA3 ABL1
12 hippocampus development GO:0021766 9.67 NME1 NKX2-1 EPHA5
13 positive regulation of phospholipase C activity GO:0010863 9.57 NTRK3 FGFR1
14 peptidyl-tyrosine phosphorylation GO:0018108 9.56 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
15 signal transduction in response to DNA damage GO:0042770 9.54 STK33 ABL1
16 cardiac muscle cell development GO:0055013 9.52 MTOR ALPK3
17 cardiac muscle fiber development GO:0048739 9.48 TTN MYO18B
18 phosphorylation GO:0016310 9.4 TTN STK33 ROS1 NTRK3 NME1 MTOR

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.18 TTN STK33 ROS1 NTRK3 NME1 MTOR
2 nucleotide binding GO:0000166 10.15 TTN STK33 ROS1 NTRK3 NME1 MYO18B
3 ATP binding GO:0005524 10.13 TTN STK33 ROS1 NTRK3 NME1 MYO18B
4 protein kinase activity GO:0004672 9.85 TTN STK33 ROS1 NTRK3 MTOR FGFR1
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.73 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
6 GPI-linked ephrin receptor activity GO:0005004 9.61 NTRK3 EPHA5 EPHA3
7 protein tyrosine kinase activity GO:0004713 9.56 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
8 ephrin receptor activity GO:0005003 9.46 EPHA5 EPHA3
9 kinase activity GO:0016301 9.4 TTN STK33 ROS1 NTRK3 NME1 MTOR
Sources

Sources for Lung Large Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....